April 2012 Policy & Advocacy Briefing Analysis of CMS Consultant Pharmacist Independence Proposal ASCP’s Policy & Advocacy Department email@example.com www.ascp.com/ltcrule
Summary No requirement for January 1, 2013 CMS believes any requirement needs to be broader in scope LTC community expected to voluntarily improve transparency immediately Measurable improvement on prevalence of unnecessary drugs, overutilization CMS plans a future notice and comment rulemaking Public comments due 60 days from Federal Register publication
Overview: Independence Policy CMS believes public comments justified concerns over conflicts of interest Does not believe CP-SNF employment represents conflict of interest Pharmacy employment relationship = financial relationship that exerts pressure Oct. 2011 proposal disproportionately targets consultant pharmacists Must consider broader changes than CP independence for a future rulemaking
Definition of Independence CMS did not respond directly to their definition or alternatives submitted through public comments No indication of whether CMS would consider modifying this definition
Alternative Approaches to Independence ASCP suggested separate contracts, fair market rates, pharmacy attestation to CP clinical independence, disclosure statements CMS considered finalizing requirements which would have included: separate contracts, fair market rates, pharmacy attestation to CP clinical independence, disclosure statements
Alternative Approaches to Independence CMS believes requiring independence is part of the right approach However other factors contribute to conflicts of interest, drug overutilization, unnecessary drugs Strongly encourages the industry to voluntarily adopt these recommendations to improve transparency
Measures for CP Performance CMS suggests industry collect data –Number of interventions –Type of interventions –Outcomes Work with PQA to develop performance measures
LTC Settings with Difficulty Complying with Proposed Independence ASCP recommended a waiver option for certain settings including rural, Tribal, closed-systems, charitable, others CMS will consider comments in a future rulemaking
Relationships with Pharma Public comments did not change CMS’s belief that CP-pharma relationships should be banned, if CP is practicing Believe that CPs receiving remuneration from pharma may be influenced Cited exchange of scientific, educational information at event supported by pharma Service in Ad boards, speaker bureaus
Timeline for Implementation CMS not finalizing at this time Changes as proposed would be disruptive Will seek a targeted less disruptive approach Expects voluntary changes from industry In the absence of measurable improvement, CMS will use future rulemaking
Cost Impact CMS acknowledges that an independence requirement would be highly disruptive to the marketplace Would result in higher costs to the nursing homes
Profession Response to the Proposal CMS did not respond specifically to the findings in ASCP’s survey Says they were swayed by comments from current and former CPs, patient advocates Believe that change is necessary
Use of Antipsychotics in NH CMS acknowledges other factors contribute to overprescribing, overutilization CMS must consider broader changes Will propose those changes in a future rulemaking
DRR Best Practices CMS says resident safety is at risk if CPs don’t have enough time to conduct a proper DRR DRR not currently yielding intended outcomes, beneficiary protections Questioning the purpose of CP DRR CMS may consider changes to the requirement to explore alternative approaches Expects industry to demonstrate value of CP DRR to resident quality of care
Enhancing medication management and the effectiveness of medication review 1.What actions/steps should be taken to strengthen attending physician (and other prescribers) medication management and prescribing practices to ensure the best quality of care for the nursing home resident? 2.What is and should be the role of nursing home medical director in overseeing the attending physician (or other prescribers) medication management activities? 3.What actions, if any, should the medical director take when attending physicians (or other prescribers) fail to engage in appropriate/adequate medication management activities?
Enhancing medication management and the effectiveness of medication review 4.What actions/steps could be undertaken to establish and ensure the independence and effectiveness of a consultant pharmacist in conducting their medication reviews on behalf of nursing home residents? 5.What training and best practice models would assist all nursing home staff to better understand behavior signs and symptoms and respond appropriately and effectively in assisting and caring for nursing home residents?
Data collection and use 6.What data are needed to enable and support the Medicare and Medicaid programs and others in monitoring the appropriateness and adequacy of medication management activities, including the use of antipsychotics drugs? 7.What data are needed to enable CMS to study the effectiveness of consultant pharmacist medication reviews? 8.What data are needed to create public performance metrics regarding the independence of consultant pharmacists and prescribers from pharmacies and drug manufacturers/distributors? 9.Are data needed on the number and type of interventions recommended by consultant pharmacists and on the outcomes of those recommendations? If so, how could such data be used and by whom?
Increasing transparency 10.What information is needed to assess the independence and adequacy of physician (and other prescriber) medication management and oversight on behalf of nursing home patients? What metrics could be used to assess the adequacy and appropriateness of prescriber response to consultant pharmacist recommendations? 11.What metrics could be used to describe the adequacy and appropriateness of a LTC facility's medication management program? 12.Describe the incentives and other arrangements that create the conflict of interest in LTC that contributes to overutilization and inappropriate drug use in LTC facilities. How can the conflict of interest stemming from these incentives and arrangements be contained
Increasing transparency 10.What specific details regarding the financial (and other) What metrics could be used to describe the adequacy and appropriateness of a LTC facility's medication management program? 11.Describe the incentives and other arrangements that create the conflict of interest in LTC that contributes to overutilization and inappropriate drug use in LTC facilities. How can the conflict of interest stemming from these incentives and arrangements be contained